Elevation Oncology, Inc. Board of Directors

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Mr. Joseph J. Ferra Jr.

Mr. Joseph J. Ferra Jr.

CEO, President & Director

Dr. David Dornan Ph.D.

Dr. David Dornan Ph.D.

Chief Scientific Officer

Mr. Biren Shah

Mr. Biren Shah

Senior Vice President of Business & Corporate Development

Candice Masse

Candice Masse

Senior Director of Corporate Communications & Investor Relations

Mr. Robert C. Yang

Mr. Robert C. Yang

Senior VP & General Counsel

Mr. Ryan Bloomer

Mr. Ryan Bloomer

Head of Tech Ops

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.